Related Experiment Video
Updated: Apr 3, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Triple therapy for atrial fibrillation and percutaneous coronary intervention
Naoual Bennaghmouch1, Willem J M Dewilde, Jurrien M ten Berg
1aDepartment of Cardiology, St Antonius Hospital, Nieuwegein bDepartment of Cardiology, Amphia Hospital Breda, the Netherlands.
Insights
For atrial fibrillation patients undergoing percutaneous coronary intervention (PCI), new strategies reduce bleeding risks. Omitting aspirin and using proton pump inhibitors after PCI improve safety of antithrombotic treatment.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) often require triple therapy (oral anticoagulation plus dual antiplatelet therapy).
- This triple therapy carries a high annual bleeding risk, often outweighing its benefits.
- Optimizing antithrombotic treatment is crucial for improving patient safety.
Purpose of the Study:
- To review current guidelines and emerging evidence for optimizing antithrombotic treatment in atrial fibrillation patients requiring oral anticoagulation and dual antiplatelet therapy.
- To evaluate the risks and benefits of various treatment options to enhance safety.
- To provide an overview of strategies for combined OAC and DAPT treatment.
Main Methods:
- Literature review of current guidelines and new evidence.
- Analysis of strategies to reduce bleeding risk during and after PCI.
- Evaluation of different antithrombotic regimens.
Main Results:
- Uninterrupted anticoagulation, radial access, and newer-generation drug-eluting stents are preferred for reducing bleeding during PCI.
- Glycoprotein receptor inhibitors should be avoided post-PCI.
- Omitting aspirin and using proton pump inhibitors after PCI significantly reduces bleeding risk compared to traditional triple therapy.
Conclusions:
- Newer strategies for antithrombotic treatment show promise in improving safety for atrial fibrillation patients undergoing PCI.
- These approaches aim to balance the need for antithrombotic efficacy with a reduced risk of bleeding.
Purpose Of Review:
Patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) require treatment with oral anticoagulation (OAC) and additional dual antiplatelet therapy with aspirin and clopidogrel (DAPT), i.e. triple therapy. However, triple therapy produces a high annual bleeding risk outweighing the benefits. To improve safety of antithrombotic treatment in these patients, the risks and benefits of all possible treatment options should be evaluated. This review provides an overview of current guidelines and new evidence for optimizing treatment of atrial fibrillation patients with an indication for combined treatment with OAC and DAPT.
Recent Findings:
To reduce bleeding risks during PCI, new evidence suggests that uninterrupted anticoagulation, radial access and the use of newer-generation drug eluting stent (DES) should be preferred. The use of glycoprotein receptor inhibitors should be avoided. After PCI, omitting aspirin seems to result in less bleeding compared with triple therapy, and the use of proton pump inhibitors further reduces bleeding risk.
Summary:
These new strategies seem to further improve the safety of antithrombotic treatment in patients with atrial fibrillation undergoing PCI.
More Related Videos
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Pericarditis III: Medical Management
Atherosclerosis III: Management
Venous Thrombosis III: Interprofessional Care

